CALLIO THERAPEUTICS
LIVE

Serial Number

99357982

Owner

Callio Operating Co, Inc.

Attorney

Joyce Liou

Filing Date

Aug 26, 2025

Add to watchlist:

No watchlists yet
View on USPTO

CALLIO THERAPEUTICS Trademark

Serial Number: 99357982

CALLIO THERAPEUTICS is a trademark filed by Callio Operating Co, Inc. on August 26, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Callio Operating Co, Inc. (4 trademarks)

1201 3rd Ave, Suite 2200-124
Seattle, WA 98101

Entity Type: 03

Trademark Details

Filing Date

August 26, 2025

Registration Date

Not Registered

Published for Opposition

July 7, 2026

Goods & Services

Research and development in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies, oncology; Providing medical scientific research information in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory anti-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies, oncology, and immunology; Drug discovery, custom design, and development services featuring therapeutic agents for the treatment and prevention of diseases; Scientific investigations for medical purposes; Scientific research in the nature of conducting clinical trials for others.

Pharmaceutical and biological preparations for treating cancer; Pharmaceuticals and biological preparations for prophylactic, diagnostic, and therapeutic use in treating, preventing, and managing cancer; Therapeutic agents for medical use, namely, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies for treating cancer; Pharmaceutical and biological preparations for the prevention, diagnosis and treatment of cancer for clinical, medicinal, therapeutic and diagnostic purposes; Pharmaceutical and biological preparations for use in oncology for treating cancer

Custom manufacturing of pharmaceuticals and therapeutic agents for medical use

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 7, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jul 7, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 1, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 5, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 22, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 21, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 21, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 21, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jan 21, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jan 21, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 15, 2026 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jan 14, 2026 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 14, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Aug 26, 2025 MAFR
NEW APPLICATION ENTERED
Aug 26, 2025 NWAP